Asset Details
Do you wish to reserve the book?
Methionine tumor starvation by erythrocyte‐encapsulated methionine gamma‐lyase activity controlled with per os vitamin B6
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Methionine tumor starvation by erythrocyte‐encapsulated methionine gamma‐lyase activity controlled with per os vitamin B6
Do you wish to request the book?
Methionine tumor starvation by erythrocyte‐encapsulated methionine gamma‐lyase activity controlled with per os vitamin B6
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Methionine tumor starvation by erythrocyte‐encapsulated methionine gamma‐lyase activity controlled with per os vitamin B6
2017
Overview
Erymet is a new therapy resulting from the encapsulation of a methionine gamma‐lyase (MGL; EC number 4.4.1.11) in red blood cells (RBC). The aim of this study was to evaluate erymet potential efficacy in methionine (Met)‐dependent cancers. We produced a highly purified MGL using a cGMP process, determined the pharmacokinetics/pharmacodynamics (PK/PD) properties of erymet in mice, and assessed its efficacy on tumor growth prevention. Cytotoxicity of purified MGL was tested in six cancer cell lines. CD1 mice were injected with single erymet product supplemented or not with vitamin B6 vitamer pyridoxine (PN; a precursor of PLP cofactor). NMRI nude mice were xenografted in the flank with U‐87 MG‐luc2 glioblastoma cells for tumor growth study following five intravenous (IV) injections of erymet with daily PN oral administration. Endpoints included efficacy and event‐free survival (EFS). Finally, a repeated dose toxicity study of erymet combined with PN cofactor was conducted in CD1 mice. Recombinant MGL was cytotoxic on 4/6 cell lines tested. MGL half‐life was increased from <24 h to 9–12 days when encapsulated in RBC. Conversion of PN into PLP by RBC was demonstrated. Combined erymet + PN treatment led to a sustained Met depletion in plasma for several days with a 85% reduction of tumor volume after 45 days following cells implantation, and a significant EFS prolongation for treated mice. Repeated injections in mice exhibited a very good tolerability with only minor impact on clinical state (piloerection, lean aspect) and a slight decrease in hemoglobin and triglyceride concentrations. This study demonstrated that encapsulation of methioninase inside erythrocyte greatly enhanced pharmacokinetics properties of the enzyme and is efficacy against tumor growth. The perspective on these results is the clinical evaluation of the erymet product in patients with Met starvation‐sensitive tumors. Methionine (Met) dependence is a cancer‐specific metabolic defect that is emerging as a target. Methionine gamma‐lyase (MGL), a bacterial Met‐catabolizing enzyme, is a promising strategy for treatment of Met‐dependent cancers despite short‐term Met depletion in vivo. In this study, the authors demonstrated that encapsulation of MGL in erythrocytes strongly improved enzyme half‐life and contributed to provide active cofactor, which overcame MGL pharmacodynamic limitations and resulted in an efficient tumor regression in a xenograft mouse model.
Publisher
John Wiley & Sons, Inc,Wiley,John Wiley and Sons Inc
Subject
/ Animals
/ Antineoplastic Agents - administration & dosage
/ Antineoplastic Agents - pharmacokinetics
/ Antineoplastic Agents - therapeutic use
/ Antineoplastic Agents - toxicity
/ Carbon-Sulfur Lyases - administration & dosage
/ Carbon-Sulfur Lyases - pharmacokinetics
/ Carbon-Sulfur Lyases - therapeutic use
/ Carbon-Sulfur Lyases - toxicity
/ Cell Proliferation - drug effects
/ Cell Survival - drug effects
/ Diet
/ Enzymes
/ Erymet
/ Humans
/ Male
/ methionine‐dependent cancers
/ Plasma
/ Pyridoxine - administration & dosage
/ Pyridoxine - pharmacokinetics
/ Pyridoxine - therapeutic use
/ Recombinant Proteins - administration & dosage
/ Recombinant Proteins - therapeutic use
/ Recombinant Proteins - toxicity
/ Studies
/ Tumors
